• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Beremagene geperpavec improves wound healing in dystrophic epidermolysis bullosa

byNhat Hung (Benjamin) LamandKiera Liblik
December 27, 2022
in Chronic Disease, Dermatology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Topical gene therapy beremagene geperpavec (B-VEC) was superior to placebo in achieving complete wound healing in patients with dystrophic epidermolysis bullosa (DEB).

2. Pruritus was the most common adverse event associated with B-VEC. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: DEB is a rare genetic skin disease caused by mutations in the COL7A1 gene, which encodes type VII collagen (C7), resulting in extensive and recurrent skin blistering. Long-term complications include an increased risk of squamous-cell carcinoma, infections, and limb deformities. No approved therapies exist for DEB. Gene-based therapies under investigation have been limited by safety concerns, the large size of the COL7A1 gene, and immune reaction to viral vectors. B-VEC is a topical gene therapy based on a replication-defective herpes simplex virus-1 carrying COLV7A1, which could circumvent these limitations. The current study was a phase three trial investigating the efficacy and safety of B-VEC in children and adults with DEB. B-VEC or placebo was administered to a treated wound and healing was compared to an untreated wound. At three and six-month follow-up visits, complete hound healing rates were significantly higher at wound sites treated with B-VEC. Patients in the B-VEC group also reported significant improvement in pain. Pruritis and chills were reported with both B-VEC and placebo. The limitations of this study were the small sample size and the predominance of smaller wounds, which have a shorter healing time. The study findings provide evidence of the efficacy of B-VEC as a corrective therapy for DEB.

Click here to read the study in NEJM

In-Depth [randomized controlled trial]: The current study was a phase three, double-blind, intra-patient randomized, placebo-controlled trial investigating the efficacy and safety of B-VEC in patients with DEB. Eligible patients were six months of age or older with symptomatic DEB confirmed by genetic testing. Exclusion criteria included participation in trials of B-VEC, concurrent immunotherapy, chemotherapy, or other investigational therapies. In a total of 31 patients, an investigator selected two open wounds of similar size, anatomical region, and appearance, and randomly assigned them 1:1 to be treated weekly with topical B-VEC or placebo for 26 weeks or until wound closure. Wound size and healing were assessed using the Canfield 2D/3D iOS imaging system. The primary endpoint was complete healing at six months. At six months, complete wound healing was observed in 67% of the wounds treated with B-VEC compared to 22% of those treated with placebo (difference, 46 percentage points; 95% Confidence Interval [CI], 24 to 68; p=0.002). Complete wound healing at three months was observed in 71% of the wounds treated with B-VEC, compared to 20% of those treated with placebo (difference, 51 percentage points; 95% CI, 29 to 73; p<0.001). At week 22, the mean change from baseline in pain severity was -0.88 with B-VEC and -0.71 with placebo (adjusted least-squares mean different, -0.61; 95% CI, -1.10 to -0.13), with differences persisting at weeks 24 and 26. Wound closure was also significantly more durable with B-VEC. Adverse events occurred in 58% of patients, the majority of which were mild or moderate and none resulted in treatment discontinuation. Squamous-cell carcinoma occurred in three patients at untreated wound sites. These findings provide evidence to support the use of B-VEC in treating DEB.

Image: PD

RELATED REPORTS

Machine renal perfusion reduces delayed graft function after transplantation

Former professional football players may be at greater risk of chronic disease

Age-related macular degeneration may be associated with depression risk

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: beremagene geperpavecchronic diseasedermatologydystrophic epidermolysis bullosagene therapytopical gene therapywound healing
Previous Post

Comparison of resuscitative endovascular balloon occlusion of the aorta versus resuscitative thoracotomy for aortic occlusion

Next Post

No significant differences in postoperative complications found between open repair with local anesthesia and laparoscopic repair of inguinal hernias

RelatedReports

State policies for organ donation may be largely ineffective
Chronic Disease

Machine renal perfusion reduces delayed graft function after transplantation

February 8, 2023
Few differences in location-stratified football-related concussions
Chronic Disease

Former professional football players may be at greater risk of chronic disease

February 7, 2023
Antioxidants, omega-3 lack benefit in age-related macular degeneration
Ophthalmology

Age-related macular degeneration may be associated with depression risk

February 6, 2023
Prevalence of hypertension among adolescents varies by race and BMI
Weekly Rewinds

2 Minute Medicine Rewind February 6, 2023

February 6, 2023
Next Post
Patient Basics: Hernia Repair

No significant differences in postoperative complications found between open repair with local anesthesia and laparoscopic repair of inguinal hernias

No association found between length of storage for transfused red blood cells and patient mortality

Ferric derisomaltose may reduce heart failure-related hospitalizations

Evidence-based interventions for pediatric asthma successfully adapted for community health centers

Emergency department crowding negative influences outcomes for adults presenting with asthma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
  • Machine renal perfusion reduces delayed graft function after transplantation
  • COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options